Volume | 75,297 |
|
|||||
News | - | ||||||
Day High | 0.412 | Low High |
|||||
Day Low | 0.38265 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Trevena Inc | TRVN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.412 | 0.38265 | 0.412 | 0.3996 | 0.4043 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
199 | 75,297 | $ 0.3921235 | $ 29,526 | - | 0.3001 - 1.12 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:00:02 | formt | 200 | $ 0.40 | USD |
Trevena Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
7.33M | 18.32M | - | 3.13M | -40.29M | -2.20 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Trevena News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRVN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.392 | 0.4369 | 0.38265 | 0.4062922 | 45,430 | 0.008 | 2.04% |
1 Month | 0.4289 | 0.4397 | 0.38 | 0.4075739 | 50,179 | -0.0289 | -6.74% |
3 Months | 0.56 | 0.568 | 0.3001 | 0.4074868 | 182,458 | -0.16 | -28.57% |
6 Months | 0.63 | 0.7693 | 0.3001 | 0.4971712 | 144,429 | -0.23 | -36.51% |
1 Year | 1.04 | 1.12 | 0.3001 | 0.7710569 | 322,796 | -0.64 | -61.54% |
3 Years | 45.75 | 55.00 | 0.3001 | 14.35 | 1,037,615 | -45.35 | -99.13% |
5 Years | 26.50 | 112.50 | 0.3001 | 40.04 | 1,909,999 | -26.10 | -98.49% |
Trevena Description
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain. |